Lung Cancer Clinical Trial
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Summary
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Eligibility Criteria
Inclusion Criteria:
histologically or cytologically proven diagnosis of malignancy other than NSCLC
positive for translocation or inversion event involving the ALK gene locus
positive for ALK amplification events
positive for ALK activating point mutations
Exclusion Criteria:
mutations of amplifications involving the c-Met gene but not the ALK gene
concurrent treatment on another therapeutic clinical trial
prior therapy specifically directed against ALK
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
Fayetteville Arkansas, 72703, United States
Rogers Arkansas, 72758, United States
Springdale Arkansas, 72762, United States
Saint Louis Missouri, 63110, United States
Las Vegas Nevada, 89169, United States
Portland Oregon, 97239, United States
Portland Oregon, 97239, United States
Portland Oregon, 97239, United States
Greenville South Carolina, 29605, United States
Beijing Chaoyang District, 10002, China
Guangzhou Guangdong, 51006, China
Monza , 20090, Italy
Monza , 20900, Italy
Nagoya Aichi, 460-0, Japan
Chuo-ku Tokyo, 104-0, Japan
Fukuoka , 811-1, Japan
Seoul , 03080, Korea, Republic of
Seoul , 06351, Korea, Republic of
Saint-Petersburg , 19702, Russian Federation
Saint-Petersburg , 19710, Russian Federation
Taipei , 100, Taiwan
How clear is this clinincal trial information?